Cell Host & Microbe

Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility

Graphical Abstract

Highlights

- Most H3N2 egg isolates carry hemagglutinin mutation G186V or L194P, but not both
- Hemagglutinin double mutation G186V/L194P is highly deleterious to the virus
- Hemagglutinin double mutation G186V/L194P disrupts the receptor-binding site
- Wild-type hemagglutinin antigenicity is maintained in G186V, but not in L194P

Authors

Nicholas C. Wu, Huibin Lv, Andrew J. Thompson, ..., James C. Paulson, Chris K.P. Mok, Ian A. Wilson

Correspondence

ch02mkp@hku.hk (C.K.P.M.), wilson@scripps.edu (I.A.W.)

In Brief

Wu et al. characterize the incompatibility between two major egg-adaptive mutations in human H3N2 virus hemagglutinin, G186V and L194P, which confer either minimal or significant antigenic change, respectively. This study suggests that the antigenically disruptive mutation L194P that occurs during egg-based influenza vaccine production can be prevented by mutational incompatibility.

Wu et al., 2019, Cell Host & Microbe 25, 836–844

June 12, 2019 © 2019 The Authors. Published by Elsevier Inc. 
https://doi.org/10.1016/j.chom.2019.04.013
Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility

Nicholas C. Wu,1 Huibin Lv,2,3 Andrew J. Thompson,4 Douglas C. Wu,5,6 Wilson W.S. Ng,2,3 Rameshwar U. Kadam,1 Chih-Wei Lin,7 Corwin M. Nycholat,4 Ryan McBride,4 Weiwen Liang,3 James C. Paulson,4,8 Chris K.P. Mok,2,3,* and Ian A. Wilson1,8,10,*

1Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
2HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
3Department of Molecular Medicine, The University of Texas at Austin, Austin, TX 78712, USA
4Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
5Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712, USA
6Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA
7Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA
8Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
9The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
10Lead Contact
*Correspondence: ch02mkp@hku.hk (C.K.P.M.), wilson@scripps.edu (I.A.W.)
https://doi.org/10.1016/j.chom.2019.04.013

SUMMARY

Egg-based seasonal influenza vaccines are the major preventive countermeasure against influenza virus. However, their effectiveness can be compromised when antigenic changes arise from egg-adaptive mutations on influenza hemagglutinin (HA). The L194P mutation is commonly observed in egg-based H3N2 vaccine seed strains and significantly alters HA antigenicity. An approach to prevent L194P would therefore be beneficial. We show that emergence of L194P during egg passaging can be impeded by preexistence of a G186V mutation, revealing strong incompatibility between these mutations. X-ray structures illustrate that individual G186V and L194P mutations have opposing effects on the HA receptor-binding site (RBS), and when both G186V and L194P are present, the RBS is severely disrupted. Importantly, wild-type HA antigenicity is maintained with G186V, but not L194P. Our results demonstrate that these epistatic interactions can be used to prevent the emergence of mutations that adversely alter antigenicity during egg adaptation.

INTRODUCTION

Seasonal influenza vaccines offer protection against two influenza virus subtypes, H1N1 and H3N2, as well as against influenza B virus. However, the effectiveness of seasonal influenza vaccines has been disappointing, especially for H3N2 viruses (Belongia et al., 2016). Their low effectiveness, other than occasional virus mismatch, can be attributed to the egg-based production process (Raymond et al., 2016; Skowronski et al., 2014; Wu et al., 2017b; Zost et al., 2017). Influenza virus hemagglutinin (HA) engages the host sialylated glycan receptor at the receptor-binding site (RBS) to initiate the virus life cycle. Growth of the virus in eggs occurs in the chorioallantoic membrane, which contains sialylated glycans that are short and are predominantly 2-3 linked (avian-type receptors) (Sriwilaijaroen et al., 2009). In contrast, sialylated glycans in human ciliated tracheal epithelial cells, which are the natural host cells for human influenza virus, are predominantly 2-6 linked (human-type receptors) (Couceiro et al., 1993). Furthermore, the receptor specificity of recent human H3N2 viruses has evolved to be mainly for long, branched 2-6 sialylated glycans (Peng et al., 2017). There is also a strong selection pressure for human H3N2 viruses to acquire mutations in the HA RBS during passaging in eggs to adapt back to the avian-type receptors present in the chorioallantoic membrane. Since the HA RBS partially overlaps with several major antigenic sites (Wiley et al., 1981; Wilson et al., 1981; Wu and Wilson, 2017), egg-adaptive mutations can dramatically alter HA antigenicity and reduce the effectiveness of seasonal influenza vaccines (Raymond et al., 2016; Skowronski et al., 2014; Wu et al., 2017b; Zost et al., 2017). While such problems can be resolved by cell-based or recombinant influenza vaccines, most influenza vaccines available on the market remain egg based because of low production cost and existing infrastructure for their annual production (Harding and Heaton, 2018).

Several egg-adaptive mutations on the HA of human H3N2 viruses, such as H156Q (Jin et al., 2005; Skowronski et al., 2014), L194P (Chen et al., 2010b; Popova et al., 2012; Wu et al., 2017b), and T160K (loss of glycosylation) (Zost et al., 2017), have been shown to affect antigenicity. However, other egg-adaptive HA mutations on human H3N2 viruses, such as H183L (Lu et al., 2005), G186V (Barrman et al., 2015; Lu et al., 2006, 2005; Parker et al., 2016; Widjaja et al., 2006), A196T (Lu et al., 2006), S219F (Widjaja et al., 2006), V226A (Lu et al., 2005), and V226I (Lu et al., 2005).
minimally impact antigenicity. While egg-adaptive mutations are critical for high-yield production of egg-based seasonal influenza vaccines, the ideal egg-based vaccine should only carry those egg-adaptive mutations that minimally affect antigenicity. As egg-based vaccines are likely to remain the major global preventive measures against seasonal influenza viruses in the foreseeable future, it is important to characterize the evolution of the influenza virus during egg adaptation.

Based on sequence database analysis and virus rescue experiments, this study revealed that the two most common egg-adaptive mutations on H3N2 HA, namely G186V and L194P, are incompatible. In other words, the HA G186V/L194P double mutant was not viable despite each of the single mutants being viable. Passaging the G186V mutant in eggs could prevent the emergence of the L194P mutation and vice versa. Structural analysis illustrated that mutations G186V and L194P had opposing structural effects. The relative height of the HA RBS is increased by G186V but decreased by L194P. This structural variation between G186V and L194P then leads to differences in the receptor-binding modes. When mutations G186V and L194P are both present, the HA RBS is disrupted, explaining the incompatibility of G186V and L194P. Consistent with previous studies (Barman et al., 2015; Chen et al., 2010b; Lu et al., 2006, 2005; Parker et al., 2016; Popova et al., 2012; Widjaja et al., 2006; Wu et al., 2017b), we also showed that G186V has minimal antigenic effect, whereas L194P strongly impacts antigenicity. In summary, this study reveals and characterizes two mutually exclusive evolutionary trajectories for egg adaptation of human H3N2 viruses, which provides important insights into the seed-strain selection for egg-based seasonal influenza vaccines.

RESULTS

Major Egg-Adaptive Mutations from Sequence Database

Egg-adaptive mutations can be readily observed after passaging human H3N2 clinical isolates in embryonated chicken eggs. To identify such mutations and ascertain their prevalence, HA protein sequences of influenza clinical isolates along with their passaging history were obtained from Global Initiative for Sharing Avian Influenza Data (GISAID; http://gisaid.org). H3 numbering is used in this study. Nine mutations, namely H156Q, H156R, H183L, G186V, L194P, S219Y, S219F, N246H, and N246S, were classified as the major egg-adaptive mutations (see STAR Methods; Figures 1A and 1B; Table S1). These observations are consistent with previous studies, which showed that growth of the H3N2 virus in eggs can be enhanced by H156Q, H156R, H183L, G186V, L194P, S219Y, S219F, N246H, and N246S, were classified as the major egg-adaptive mutations (see STAR Methods; Figures 1A and 1B; Table S1).
Hartgroves et al., 2010; Stevens et al., 2010), S219Y (Meyer et al., 1993; Parker et al., 2016; Stevens et al., 2010), S219F (Parker et al., 2016; Widjaja et al., 2006), and loss of a glycosylation site at position 246 (Barman et al., 2015). These seven major egg-adaptive mutations are all located within or adjacent to the HA RBS (Figure 1B). Among them, G186V and L194P, which are located on opposite sides of the 190-helix, had particularly high-occurrence frequencies (Figure 1A).

We further examined the protein sequences of nine H3N2 vaccine seed strains that were used for egg-based influenza vaccine production (Table S2). Six of the nine major egg-adaptive mutations, H156Q, H156R, G186V, L194P, S219Y, and S219F, could be found in the vaccine seed strains (Figure 1C). The most commonly observed egg-adaptive mutations among these nine vaccine seed strains were G186V and L194P, each of which was carried by four vaccine seed strains. However, none of the nine vaccine seed strains carried both G186V and L194P.

The H3N2 vaccine seed stock for the 2009–2010 northern hemisphere influenza season was derived from A/Uruguay/716/2007, which was antigenically equivalent to A/Brisbane/10/2007 (Bris07). A/Uruguay/716/2007 (NYMC X-175C) carried an egg-adaptive mutation, L194P, which has been extensively characterized, both structurally and antigenically, in our previous study using Bris07 HA (Wu et al., 2017b). Interestingly, two egg-adapted strains that were derived from Bris07, namely NYMC X-171 and IVR-147, carried different egg-adaptive mutations (Figure 1C). While NYMC X-171 carried mutation G186V but not L194P, IVR-147 carried mutation L194P but not G186V. Recently, the World Health Organization (WHO) announced A/Kansas/14/2017 (Kansas17) as the H3N2 vaccine strain for the 2019–2020 northern hemisphere influenza season. Therefore, we also examined the sequences of four egg-adapted strains that were derived from Kansas17 (Figure 1D). Consistent with our observations above, these four strains carried G186V but not L194P. Overall, this analysis demonstrates the potential clinical relevance of the egg-adaptive mutations and further suggests that G186V and L194P represent two distinct evolutionary pathways for egg adaptation.

**Incompatibility of G186V and L194P**

Next, we aimed to investigate whether there was any relationship between G186V and L194P. Based on the egg-passaged human H3N2 virus in the GISAID database, a network diagram was constructed to visualize the co-occurrence of the nine major egg-adaptive mutations (Figures 2A; see STAR Methods). In this network diagram, each node represents an egg-adaptive mutation. Two mutations that co-occur more than once are connected by an edge. The occurrence frequency of each egg-adaptive mutation is color coded. L183 is not shown because it does not co-occur with other major egg-adaptive mutations in more than one isolate.

We also performed a virus rescue experiment (Figure 2B). Both G186V and L194P single mutants could be rescued to a reasonable titer despite the lower titer of the L194P mutant. In contrast, the G186V/L194P double mutant could not be rescued. This result is consistent between two H3N2 genetic backgrounds: namely A/Victoria/361/2011 (Vic11) and Bris07. In fact, a previous study also failed to rescue the G186V/L194P double mutant in Bris07, as well as in another human H3N2 strain A/Wisconsin/67/05 (Chen et al., 2010b). Overall, our analyses show that G186V and L194P are incompatible.
Previously, we performed a thorough structural study of the compatibility of G186V and L194P. G186V and L194P mutants are different, corroborating the in-the-evolutionary-trajectories-during-H3N2-egg-adaptation-of-residue-190 (C (Wu et al., 2017b), Vic11: PDB 4O5N (Lee et al., 2014), and Mich14: PDB 6BKP et al., 2012), Bris07: PDB 6AOR (Wu et al., 2017b), Bris07 (L194P): PDB 6AOP (Wu et al., 2018), Fin04: PDB 2YP2 (Lin et al., 2012), HK05: PDB 2YP7 (Lin (Wu et al., 2018).)

A zoomed-in view of the RBS backbone shift.

The distances between the phenolic oxygen of Tyr 98 (OH98) and the C of residue 190 (C190) in different H3 strains were measured: Wy03: PDB 6BKN (Wu et al., 2018), Fin04: PDB 2YP2 (Lin et al., 2012), HK05: PDB 2YP7 (Lin et al., 2012), Bris07: PDB 6AOR (Wu et al., 2017b), Bris07 (L194P): PDB 6AOP (Wu et al., 2017b), Vic11: PDB 4OSN (Lee et al., 2014), and Mich14: PDB 6BKP (Wu et al., 2018).

G186V and L194P Lead to Differences in Receptor-Binding Mode

To understand how G186V influences receptor binding, crystal structures of IVR-165 HA in complex with the avian receptor analog NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAc (3’SLNLN) and the human receptor analog NeuAcα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAc (6’SLNLN) were determined at 2.1 and 2.4 Å, respectively (Table S3; Figure S2). When binding to IVR-165 HA, 3’SLNLN adopts an extended conformation (Figure 4A), whereas 6’SLNLN adopts the canonical folded-back conformation (Figure 4B). We also observed a shift of the 220-loop toward the RBS during receptor binding (Figures 4A and 4B), which is a typical feature of recent human H3 viruses (Lin et al., 2012). Similar to our previous observation with Bris07 L194P HA (Wu et al., 2017b), IVR-165 HA had negligible binding to the glycan array (Figure S3). Of note, the glycan array has more stringent requirements for the detection of receptor binding than the X-ray structure analysis here, which involves soaking the crystals in a 100-fold molar excess of the receptor analogs. Being able to observe electron density for the receptor analogs in our crystal structures but no signal in the glycan array experiments indicates very weak binding to the receptor. This result also substantiates the notion that efficient replication of human influenza virus in chicken eggs does not require strong binding between HA and sialylated receptors (Wu et al., 2017b).

G186V Increases the Height of the HA RBS

We postulated that since G186V and L194P are mutually exclusive, the evolutionary trajectories of the H3N2 virus in eggs would be influenced by whichever mutation (i.e., G186V or L194P) appears first. We then performed an experiment by passaging the Bris07 G186V mutant to monitor the emergence of any mutations in the HA receptor-binding subdomain (HA1 residues 117–265) using next-generation sequencing. The G186V mutant was passaged in eggs in triplicate (Figure 2C). As expected, when the G186V mutant was passaged in eggs, the L194P mutation did not emerge. Instead, mutations I140K, I140R, N144K, H156R, H156Q, N189K, and D190N were observed with a frequency of >10% (Table S3; Figure S2). Overall, these results demonstrate that the evolutionary trajectories during H3N2 egg adaptation of G186V and L194P mutants are different, corroborating the incompatibility of G186V and L194P.

Figure 3. Structural Comparison of IVR-165 HA and Vic11 HA
(A) The HA RBS conformations of IVR-165 HA and Vic11 HA were compared by aligning their receptor-binding subdomains (HA1 residues 117–265). The slight expansion of the RBS due to the backbone shifts of the 190-helix and 220-loop is indicated by the arrows. IVR-165 HA that was used for structural determination was expressed recombinantly in insect cells (see STAR Methods).

Figure 4. Structural Comparison of IVR-165 HA and Vic11 HA
(A) The HA RBS conformations of IVR-165 HA and Vic11 HA were compared by aligning their receptor-binding subdomains (HA1 residues 117–265) using next-generation sequencing. The G186V mutation, which causes the 190-helix to move away from the 220-loop through an increase in the side-chain volume. The other two egg-adaptive mutations H156Q and S219Y have little, if any, influence on the distance between the 190-helix and 220-loop. H156Q abolishes a hydrogen bond between the 150-loop and 190-helix (Figures S1A and S1B), whereas S219Y stabilizes the N165 glycan from the neighboring promoter of the trimer by forming a stacking interaction with the glycan (Figure S1C). Therefore, the observed distance increase between the 190-helix and 220-loop is mainly a result of the G186V mutation.

We further compared the height of the HA RBS of IVR-165 with that of other H3 strains (Figure 3C), namely A/Wyoming/3/2003 (Wy03) (Wu et al., 2018), A/Finnland/486/2004 (Fin04) (Lin et al., 2012), A/Hong Kong/4443/2005 (HK05) (Lin et al., 2012), Bris07 (Wu et al., 2017b), Vic11 (Lee et al., 2014), and A/Michigan/15/2014 (Mich14) (Wu et al., 2018). Besides IVR-165 HA, Wy03 HA also carried the G186V mutation. The heights of the RBS of Wy03 and IVR-165, as measured by the distance between OH98 and C190, are 9.3 and 9.5 Å, respectively. In comparison, those equivalent distances of Fin04, HK05, Bris07, Vic11, and Mich14 are in the range of 8.5–8.8Å. Overall, our structural analysis indicates that G186V increases the height and, hence, the size of the HA RBS.
Interestingly, noticeable differences can be observed between the receptor-binding modes of IVR-165 HA and that of the Bris07 HA L194P mutant (Wu et al., 2017b) when their receptor-binding subdomains (HA1 residues 117–265) are aligned (Figures 4C and 4D). GlcNAc-3 of the $3\text{SLNLN}$ in complex with the Bris07 HA L194P mutant shifts away from the RBS as compared to that of $3\text{SLNLN}$ in complex with IVR-165 HA (Figure 4C). For $6\text{SLNLN}$, Gal-2 is rotated by $90^\circ$ when binding to Bris07 HA L194P (Wu et al., 2017b), as compared to the folded-back conformation when binding to IVR-165 HA (Figure 4D). Such differences in receptor binding can be attributed to the difference in the positioning of the 190-helix, i.e., the height of the RBS. In contrast to mutation G186V, which increases the RBS height, mutation L194P appears to decrease its height (Figure 3C). The distance between OH$_{98}$ and C$_{\alpha_{190}}$ of the Bris07 HA L194P mutant is 8.3 Å, whereas that of Bris07 wild-type (WT) HA is 8.7 Å. We further measured the difference in backbone conformations between the receptor-binding subdomains of Bris07 and IVR-165 HA in their receptor-bound states (Figure 4E). This analysis reveals that shifts in the polypeptide backbone between Bris07 HA and IVR-165 HA in the 190-helix can be as large as 3 Å. Consequently, the difference in receptor-binding mode between IVR-165 HA and the Bris07 HA L194P mutant can be explained by the opposing structural effects of the G186V and L194P mutations.

HA G186V/L194P Double Mutant Disrupts the RBS

With the knowledge that HA mutations G186V and L194P exert an opposing structural effect on the RBS (Figures 3C, 4C, and 4D) and that the HA G186V/L194P double mutant was highly deleterious to the virus (Figure 2B), we were interested in examining the structural effect of the HA G186V/L194P double mutant. Of note, the HA G186V/L194P double mutant abolishes virus replication but not HA protein expression. We were therefore able to recombinantly express and purify the Bris07 HA G186V/L194P double mutant. Crystal structures of the Bris07 HA G186V/L194P double mutant were determined at 2.25 Å, 2.1 Å, and 2.4 Å for the apo form, in complex with $3\text{SLNLN}$, and in complex with $6\text{SLNLN}$, respectively. In all three structures, the electron density for the 190-helix was very weak to absent compared to that of the Bris07 HA L194P single mutant (Figure 5), whose structure was previously determined in the same crystallization condition (Wu et al., 2017b). This observation indicates that the 190-helix in Bris07 HA G186V/L194P double mutant is extremely disordered. Consistently, the electron density for the receptor analogs $3\text{SLNLN}$ and $6\text{SLNLN}$ was also very weak in the complex with
the Bris07 HA G186V/L194P double mutant. This structural analysis shows that combining HA mutations G186V and L194P dramatically destabilizes the 190-helix, causing a disruption of the RBS and also of antigenic site B, which is the major antigenic site in recent H3N2 viruses (Broecker et al., 2018; Popova et al., 2012).

G186V Imposes Minimum Change in Antigenicity

Previously, we and others demonstrated that the HA antigenicity is significantly altered by the L194P mutation (Chen et al., 2010b; Popova et al., 2012; Wu et al., 2017b), when using ferret sera (Chen et al., 2010b), human sera (Wu et al., 2017b), and human monoclonal antibodies (Popova et al., 2012; Wu et al., 2017b). Furthermore, based on a ferret study, L194P has been shown to significantly decrease virus immunogenicity (Chen et al., 2010b). In contrast, the G186V mutation has been shown to confer minimal HA antigenic differences (Barman et al., 2015; Lu et al., 2006, 2005; Parker et al., 2016; Widjaja et al., 2006, 2005, 2014; Wu et al., 2017b; Zost et al., 2017), some HA egg-adaptive mutations do not affect antigenicity (Barman et al., 2015; Lu et al., 2006, 2005; Parker et al., 2016; Widjaja et al., 2006). Sera from ferrets that were immunized with a virus that carried the G186V mutation cross-react well with the WT virus, with only a 2-fold decrease in hemagglutination inhibition (HAI) titers compared to the sera from ferrets that were immunized with the WT virus (Barman et al., 2015). Here, we further performed a side-by-side comparison of the HA antigenic changes resulting from the G186V and L194P mutations. Sera from six mice that were immunized with unpassaged Bris07 WT virus (6:2 reassortant on PR8 backbone) were obtained. The immunization scheme consisted of infection of BALB/c mice with a non-adenovirused virus followed by a boost with an Addavax-adjuvanted virus. An ELISA experiment was then performed to assess binding of these sera to Bris07 WT, G186V, and L194P recombinant HA proteins (Figures 6A and S4A). For all serum samples, the binding to G186V was almost as strong as to WT, whereas binding to L194P was consistently weaker than to WT or G186V. We also tested binding of the HA-RBS-targeted antibody C05 (Ekiert et al., 2012) to Bris07 WT, G186V, and L194P recombinant HA proteins using biolayer interferometry (BLI) (Figure 6B). C05 exhibited high affinity to WT (K_d = 1.0 ± 0.1 nM) and to G186V (K_d = 1.4 ± 0.2 nM), but very weak binding to L194P (>1,000 nM). As a positive control, the stem-binding antibody CR9114 (Dreyfus et al., 2012) bound equally well to all three recombinant proteins (Figure S4B). Overall, these results substantiate the conclusion that G186V, unlike L194P (Chen et al., 2010b; Popova et al., 2012; Wu et al., 2017b), exhibits minimal antigenic change (Barman et al., 2015; Lu et al., 2006, 2005; Parker et al., 2016).

DISCUSSION

Non-additivity of mutational fitness effects is known as epistasis. Our previous studies have shown that epistasis is prevalent in the HA RBS (Wu et al., 2017a) and is relevant to antigenic drift of circulating human H3N2 influenza viruses (Wu et al., 2018). This study further demonstrates that epistasis also exists between egg-adaptive mutations in the HA RBS. Mutational incompatibility between G186V and L194P is an extreme form of epistasis and can be attributed to their opposing structural effects. It is perhaps surprising that human H3N2 virus can adapt to eggs via two mutually exclusive pathways. Egg adaptation of influenza virus involves a receptor tropism switch, as required also in reverse for successful avian-to-human transmission that underlies human influenza pandemics (Shi et al., 2014). However, it remains to be explored whether multiple mutational strategies can be employed by a single influenza strain to switch receptor specificity during avian-to-human transmission.

While the low effectiveness of egg-based, seasonal influenza vaccines has been attributed to HA egg-adaptive mutations that alter the antigenicity (Raymond et al., 2016; Skowronsiki et al., 2014; Wu et al., 2017b; Zost et al., 2017), some HA egg-adaptive mutations do not affect antigenicity (Barman et al., 2015; Lu et al., 2006, 2005; Parker et al., 2016; Widjaja et al., 2006). Interestingly, our work here revealed that different HA egg-adaptive mutations may not be compatible with each other. Our results raise the possibility that during egg-based seasonal vaccine production, the emergence of an egg-adaptive mutation with undesirable antigenic properties can be prevented by the presence of another egg-adaptive mutation by taking advantage of epistatic interactions.

Our study provides valuable information for the selection of vaccine seed strains with mutations that not only support
efficient replication in eggs but also minimally affect the antigenicity when passaging in eggs. While the ideal approach would be to engineer the desired mutations into the vaccine seed stock using reverse genetics, such an approach is not allowed in certain countries because of their regulation on genetically modified organisms (GMOs). Alternatively, multiple egg-adapted isolates from the same parental strain can be plaque isolated and sequenced. Isolates that carry the desired mutations can then be selected for the vaccine seed strain. Of note, different egg-adapted isolates from the same parental strain often carry different mutations (Barman et al., 2015; Parker et al., 2016). For example, both NYMC X-171 and IVR-147 were derived from the same parental strain Bris07 yet carried different egg-adaptive mutations (Figure 1C). Screening egg-adapted isolates that carry desired mutations may therefore represent a cost-effective approach for selecting the vaccine seed strain. Further studies will need to evaluate the complete inventory of possible egg-adaptive mutations, their antigenicity, and their compatibility with each other. Other related questions that need to be addressed include how different egg-adaptive mutations impact immunogenicity in different age cohorts and how antigenic imprinting (Henry et al., 2019; Lee et al., 2019) influences the immune response elicited by egg-grown influenza vaccines.

Egg-based seasonal influenza vaccines have been the primary preventive against the influenza virus for more than 70 years (Hajj Hussein et al., 2015) despite the caveat of antigenic changes due to egg-adaptive mutations (Raymond et al., 2016; Skowronska et al., 2014; Wu et al., 2017b; Zost et al., 2017). While our work has an immediate impact on the egg-based vaccine seed-strain selection process, a more radical approach is needed in the long run to provide substantial improvements in influenza vaccines. For example, Harding et al. recently developed a dual-HA influenza virus to enable efficient vaccine production in eggs without the need for egg adaptation (Harding et al., 2017). Alternatively, several non-egg-based influenza vaccines have been developed (Harding and Heaton, 2018). Commercialization of cell-based (CDC, 2018a) and recombinant influenza vaccines (CDC, 2018b) that have been developed during the past decade will hopefully completely replace egg-based seasonal vaccines, albeit even if subject to a slow transition. However, the ultimate solution to influenza may require the development of a universal influenza vaccine that can offer long-lasting protection against multiple strains and subtypes (Erbelding et al., 2018).

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- CONTACT FOR REAGENT AND RESOURCE SHARING
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Cell Cultures
  - Influenza Virus
- METHOD DETAILS
  - Sequence Analysis
  - Construction of Individual Mutants
  - Serial Passages of the Influenza Viruses in Eggs
  - Expression, Crystallization and Structural Determination
  - Glycan Array Analysis
  - Immunization of the Influenza Virus in Mice
  - Antigen Binding Assay
  - IgG Expression and Purification
  - Biolayer Interferometry Binding Assay
- QUANTIFICATION AND STATISTICAL ANALYSIS
- DATA AND SOFTWARE AVAILABILITY

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.chom.2019.04.013.

ACKNOWLEDGMENTS

We thank Steven Head, Jessica Ledesma, and Padmaja Natarajan at TSRI Next Generation Sequencing Core for next-generation sequencing and Henry Tien for technical support with the crystallization robot. We acknowledge NIH R56 AI127371 (I.A.W.), NIH R01 AI114730 (J.C.P.), the Bill and Melinda Gates
Foundation OPP1170236 (I.A.W.), the Bill and Melinda Gates Foundation Post-Doctoral Fellowship in Global Health (N.C.W.), the Theme Based Research Scheme (Ref: T11-705/14N) from Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China, and Guangzhou Medical University High Level University Construction Project Funding (H.L., W.W.S.N., W.L., and C.K.P.M.) for support.

AUTHOR CONTRIBUTIONS

N.C.W., C.K.P.M., and I.A.W. conceived and designed the study. N.C.W. and D.C.W. performed the sequence database analysis. N.C.W. performed the virus rescue experiment. N.C.W., W.W.S.N., and C.K.P.M. performed the egg-passageing experiment. A.J.T., R.M., and J.C.P. performed the glycan array experiment. C.M.N. and J.C.P. synthesized the 3'SLNLN and 6'SLNLN. N.C.W. performed the X-ray crystallography. R.U.K. crystalized the IVR-165 HA. H.L., W.L., and C.K.P.M. performed the mouse immunization and ELISA experiments. N.C.W. performed the biolayer interferometry experiment. N.C.W., C.K.P.M., and I.A.W. wrote the paper, and all authors reviewed and edited the paper.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: January 22, 2019
Revised: April 1, 2019
Accepted: April 26, 2019
Published: May 28, 2019

WEB RESOURCES

Global Initiative on Sharing All Influenza Data: https://www.gisaid.org

REFERENCES

Barman, S., Franks, J., Turner, J.C., Yoon, S.W., Webster, R.G., and Webby, R.J. (2015). Egg-adaptive mutations in H3N2v vaccine virus enhance egg-based production without loss of antigenicity or immunogenicity. Vaccine 33, 3186–3192.

Belongia, E.A., Simpson, M.D., King, J.P., Sundaram, M.E., Kelley, N.S., Osterholm, M.T., and McLean, H.O. (2016). Variable influenza virus effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect. Dis. 16, 942–951.

Broecker, F., Liu, S.T.H., Sun, W., Krammer, F., Simon, V., and Palese, P. (2013). Egg-adaptive mutations in H3N2v vaccine virus enhance egg-growth in embryonated chicken eggs. Vaccine 31, 8940–8948.

Chen, V.B., Arendall, W.B., 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., Murray, L.W., Richardson, J.S., and Richardson, D.C. (2010a). MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21.

CDC. (2018a). Cell-based flu vaccines. https://www.cdc.gov/flucdc2018/protection/vaccine/cell-based.htm.

CDC. (2018b). Recombinant influenza (flu) vaccine. https://www.cdc.gov/flucdc2018/protection/vaccine/qa_flublok-vaccine.htm.

Chen, V.B., Arendall, W.B., 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., Murray, L.W., Richardson, J.S., and Richardson, D.C. (2010a). MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21.

Chen, Z., Zhou, H., and Jin, H. (2010b). The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response. Vaccine 28, 4079–4085.

Couceiro, J.N., Paulson, J.C., and Baum, L.G. (1993). Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res. 29, 155–165.

Dreyfus, C., Laursen, N.S., Kwaks, T., Zuijdgeest, D., Khayat, R., Ekiert, D.C., Lee, J.H., Mettigel, Z., Banj, M.V., Jongeneelen, M., et al. (2012). Highly conserved protective epitopes on influenza B viruses. Science 337, 1343–1348.

Ekiert, D.C., Friesen, R.H., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., Ophorst, C., Cox, F., Korse, H.J., Brandenburg, B., et al. (2011). A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843–850.

Ekis, D.C., Kashyap, A.K., Steel, J., Rubrum, A., Bhabha, G., Khayat, R., Lee, J.H., Dillon, M.A., O’Neill, R.E., Faynboym, A.M., et al. (2012). Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526–532.

Emseley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development of coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501.

Erbelding, E.J., Post, D.J., Stemmy, E.J., Roberts, P.C., Augustine, A.D., Ferguson, S., Paules, C.I., Graham, B.S., and Fauci, A.S. (2018). A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. J. Infect. Dis. 218, 347–354.

Hajj Hussein, I., Chams, N., Chams, S., El Sayegh, S., Badran, R., Raad, M., Gerges-Geagea, A., Leone, A., and Jurus, A. (2015). Vaccines through centuries: major cornerstones of global health. Front. Public Health 3, 269.

Harding, A.T., Heaton, B.E., Dumm, R.E., and Heaton, N.S. (2017). Rationally designed influenza virus vaccines that are antigenically stable during growth in eggs. mBio 8, e00669–e00617.

Harding, A.T., and Heaton, N.S. (2018). Efforts to improve the seasonal influenza vaccine. Vaccines (Basel) 6, E19.

Hartgroves, L.C., Koudstaal, W., McLeod, C., Moncorge, O., Thompson, C.J., Ellis, J., Bull, C., Havenga, M.J., Goudsmitt, J., and Barclay, W.S. (2010). Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. Vaccine 28, 2973–2979.

Henry, C., Zheng, N.Y., Huang, M., Cabanon, A., Rojas, K.T., Kaur, K., Andrews, S.F., Palm, A.E., Chen, Y.Q., Li, Y., et al. (2019). Influenza virus vaccination elicits poorly adapted B cell responses in elderly individuals. Cell Host Microbe 25, 357–366.e6.

Jin, H., Zhou, H., Liu, H., Chan, W., Adhikary, L., Mahmood, K., Lee, M.S., and Kemble, G. (2005). Two residues in the hemagglutinin of A/Fujian/411/02-like influenza viruses are responsible for antigenic drift from A/Panama/2007/99. Virology 336, 113–119.

Katoh, K., and Standley, D.M. (2013). MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772–780.

Lee, J., Paparoditis, P., Horton, A.P., Fruhwirth, A., McDaniel, J.R., Jung, J., Boutz, D.R., Hussein, D.A., Tanno, Y., Pappas, L., et al. (2019). Persistent antibody clonotypes dominate the serum response to influenza over multiple years and repeated vaccinations. Cell Host Microbe 25, 367–376.e5.

Lee, P.S., Ohshima, N., Stanfield, R.L., Yu, W., Iba, Y., Okuno, Y., Kurosawa, Y., and Wilson, I.A. (2014). Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Nat. Commun. 5, 3614.

Lin, Y.P., Xiong, X., Wharton, S.A., Martin, S.R., Coombs, P.J., Vachiery, S.G., Christodoulou, E., Walker, P.A., Liu, J., Skehel, J.J., et al. (2012). Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc. Natl. Acad. Sci. USA 109, 21474–21479.

Lu, B., Zhou, H., Chan, W., Kemble, G., and Jin, H. (2006). Single amino acid substitutions in the hemagglutinin of influenza A/Singapore/21/04 (H3N2) increase virus growth in embryonated chicken eggs. Vaccine 24, 6691–6693.

Lu, B., Zhou, H., Ye, D., Kemble, G., and Jin, H. (2005). Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics. J. Virol. 79, 6763–6771.

Mccoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007). Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674.

McWhite, C.D., Meyer, A.G., and Wilke, C.O. (2016). Sequence amplification via cell passaging creates spurious signals of positive adaptation in influenza virus H3N2 hemagglutinin. Virus Evol. 2, eav026.

Meyer, W.J., Wood, J.M., Major, D., Robertson, J.S., Webster, R.G., and Katz, J.M. (1993). Influence of host cell-mediated variation on the international surveillance of influenza A (H3N2) viruses. Virology 196, 130–137.

Murshudov, G.N., Skubak, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A., Nicholls, R.A., Winn, M.D., Long, F., and Vagin, A.A. (2011). REFMAC5 for
the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355–367.

Neumann, G., Watanabe, T., Ito, H., Watanabe, S., Goto, H., Gao, P., Hughes, M., Perez, D.R., Donis, R., Hoffmann, E., et al. (1999). Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA 96, 9345–9350.

Otwinowski, Z., and Minor, W. (1997). Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326.

Parker, L., Wharton, S.A., Martin, S.R., Cross, K., Lin, Y., Liu, Y., Feizi, T., Daniels, R.S., and McCauley, J.W. (2016). Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses. J. Gen. Virol. 97, 1333–1344.

Peng, W., de Vries, R.P., Grant, O.C., Thompson, A.J., McBride, R., Tsogtbaatar, B., Lee, P.S., Razi, N., Wilson, I.A., Woods, R.J., et al. (2017). Recent H3N2 viruses have evolved specificity for extended, branched human-type receptors, conferring potential for increased avidity. Cell Host Microbe 21, 23–34.

Popova, L., Smith, K., West, A.H., Wilson, P.C., James, J.A., Thompson, L.F., and Air, G.M. (2012). Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One 7, e41895.

Raymond, D.D., Stewart, S.M., Lee, J., Ferdman, J., Bajic, G., Do, K.T., Emandes, M.J., Suphaphiphat, P., Settembre, E.C., Dormitzer, P.R., et al. (2016). Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nat. Med. 22, 1465–1469.

Shi, Y., Wu, Y., Zhang, W., Qi, J., and Gao, G.F. (2014). Enabling the ‘host jump’: structural determinants of receptor-binding specificity in influenza A viruses. Nat. Rev. Microbiol. 12, 822–831.

Skowronski, D.M., Janjua, N.Z., De Serres, G., Sabin, S., Eshagh, A., Dickson, J.A., Fonseca, K., Winter, A.L., Gubbay, J.B., Krajden, M., et al. (2014). Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 9, e92153.

Snijders, N., Kondo, S., Yagi, H., Wilairet, P., Hiramatsu, H., Ito, M., Ito, Y., Kato, K., and Suzuki, Y. (2009). Analysis of N-glycans in embryonated chicken egg chorioallantoic and amniotic cells responsible for binding and adaptation of human and avian influenza viruses. Glycoconj. J. 26, 433–443.

Stevens, J., Chen, L.M., Carney, P.J., Garten, R., Foust, A., Le, J., Pokorny, B.A., Manojkumar, R., Silverman, J., Devis, R., et al. (2010). Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs. J. Virol. 84, 8287–8299.

Widjaja, L., Ilyushina, N., Webster, R.G., and Webby, R.J. (2006). Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs. Virology 350, 137–145.

Wiley, D.C., Wilson, I.A., and Skehel, J.J. (1981). Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289, 373–378.

Wilson, I.A., Skehel, J.J., and Wiley, D.C. (1981). Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 299, 366–373.

Wu, N.C., Thompson, A.J., Xie, J., Lin, C.W., Nycholat, C.M., Zhu, X., Lerner, R.A., Paulson, J.C., and Wilson, I.A. (2018). A complex epistatic network limits the mutational reversibility in the influenza hemagglutinin receptor-binding site. Nat. Commun. 9, 1264.

Wu, N.C., and Wilson, I.A. (2017). A perspective on the structural and functional constraints for immune evasion: insights from influenza virus. J. Mol. Biol. 429, 2694–2709.

Wu, N.C., Xie, J., Zheng, T., Nycholat, C.M., Grande, G., Paulson, J.C., Lerner, R.A., and Wilson, I.A. (2017a). Diversity of functionally permissive sequences in the receptor-binding site of influenza hemagglutinin. Cell Host Microbe 21, 742–753.e8.

Zost, S.J., Parkhouse, K., Gumina, M.E., Kim, K., Diaz Perez, S., Wilson, P.C., Treanor, J.J., Sant, A.J., Cobey, S., and Hensley, S.E. (2017). Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl. Acad. Sci. USA 114, 12578–12583.
### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| DMEM medium         | Thermo Fisher Scientific | Cat#11995065 |
| DMEM/F12 medium     | Thermo Fisher Scientific | Cat#11320033 |
| ExpiCHO Expression System Kit | Thermo Fisher Scientific | Cat#A29133 |
| HyClone insect cell culture medium | GE Healthcare | Cat#SH30280.03 |
| MEM non-essential amino acids | Thermo Fisher Scientific | Cat#11440050 |
| Trypsin-EDTA        | Thermo Fisher Scientific | Cat#25200056 |
| Penicillin-Streptomycin | Thermo Fisher Scientific | Cat#15140122 |
| Fetal Bovine Serum (FBS) | Thermo Fisher Scientific | Cat#16000044 |
| Phosphate-buffered saline (PBS) | Thermo Fisher Scientific | Cat#14040133 |
| Lipofectamine 2000  | Thermo Fisher Scientific | Cat#11668019 |
| Ni-NTA Superflow    | Qiagen | Cat#30450 |
| HA protein sequences | GISAID; [http://gisaid.org](http://gisaid.org) | N/A |
| DH10Bac competent cells | Thermo Fisher Scientific | Cat#10361012 |
| BALB/c mice         | Laboratory Animal Unit at HKU | N/A |

**Antibodies**

- C05 [Ekiert et al., 2012](http://example.com) | N/A |
- CR9114 [Dreyfus et al., 2012](http://example.com) | N/A |
- Anti-HIS mouse antibody | Thermo Fisher Scientific | Cat#MA1-21315; RRID: AB_557403 |
- Alexa647-linked anti-mouse IgG | Thermo Fisher Scientific | Cat#A-21235; RRID: AB_141693 |

**Chemicals and Recombinant Proteins**

- DpnI | New England Biolabs | Cat#R0176L |
- Trypsin | New England Biolabs | Cat#P81015 |
- TPCK-Trypsin | Thermo Fisher Scientific | Cat#20233 |
- RNaseOUT | Thermo Fisher Scientific | Cat#10777019 |
- Sodium chloride (NaCl) | Sigma-Aldrich | Cat#S9888 |
- Tris Base | Sigma-Aldrich | Cat#11812473001 |
- Concentrated hydrochloric acid (HCl) | Sigma-Aldrich | Cat#H1758 |
- Sodium azide (NaN₃) | Sigma-Aldrich | Cat#S2002 |
- Bovine Serum Albumin (BSA) | Sigma-Aldrich | Cat#A9418 |
- Tween 20 | Fisher Scientific | Cat#BP337-500 |
- 3’SLNLN | In-house synthesis | N/A |
- 6’SLNLN | In-house synthesis | N/A |
- Chemicals for protein crystallization | Hampton Research | N/A |
- Addavax | InvivoGen | Cat#vac-adx-10 |

**Critical Commercial Assays**

- In-Fusion HD Cloning Kit | Takara | Cat#639647 |
- KOD Hot Start DNA Polymerase | EMD Millipore | Cat#71086-3 |
- PCR Clean-Up and Gel Extraction Kit | Clontech Laboratories | Cat#740609.250 |
- QIAprep Spin Miniprep Kit | Qiagen | Cat#27106 |
- NucleoBond Xtra Maxi | Clontech Laboratories | Cat#740414.100 |
- Superscript III reverse transcriptase | Thermo Fisher Scientific | Cat#18080044 |
- QIAamp Viral RNA Mini Kit | Qiagen | Cat#52904 |
- QuikChange XL Mutagenesis kit | Stratagene | Cat#200516 |

(Continued on next page)
Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Deposited Data      |        |            |
| Raw sequencing reads| This study | BioProject PRJNA532726 |
| X-ray coordinates and structure factors | This study | PDB: 6NS9, 6NSA, 6NSB, 6NSC, 6NSF, 6NSG |
| Cell Lines          |        |            |
| HEK 293T cells      | N/A    | N/A        |
| MDCK-SIA1 cells     | Sigma-Aldrich | Cat#05071502-1VL |
| HEK 293S GnTI<sup>−</sup> cells | ATCC | ATCC CRL-3022 |
| ExpiCHO cells       | Thermo Fisher Scientific | Cat#A29127 |
| Sf9 cells           | ATCC | ATCC CRL-1711 |
| High Five cells     | Thermo Fisher Scientific | Cat#B85502 |
| Oligonucleotides    |        |            |
| Bris07-G186V-F:     | Integrated DNA Technologies | N/A |
| 5'-GGG GTT CAC CCG GTT ACG GAC AAT GAC CAA-3' | |
| Bris07-G186V-R:     | Integrated DNA Technologies | N/A |
| 5'-TTG GTC ATT GTG CGT AAC CGG GTG GTG AAC CCC-3' | |
| Bris07-L194P-F:     | Integrated DNA Technologies | N/A |
| 5'-AAT GAC CAA ATC TTC TAT GCT CAA GCA TCA-3' | |
| Bris07-L194P-R:     | Integrated DNA Technologies | N/A |
| 5'-TGA TGC TTG AGC ATA CGG GAA GAT TTG GTC ATT-3' | |
| Vic11-G186V-F:      | Integrated DNA Technologies | N/A |
| 5'-GGG GTT CAC CCG GTT ACG GAC AAG GAC CAA-3' | |
| Vic11-G186V-R:      | Integrated DNA Technologies | N/A |
| 5'-TTG GTC CTT GTG CGT AAC CGG GTG GTG AAC CCC-3' | |
| Vic11-L194P-F:      | Integrated DNA Technologies | N/A |
| 5'-AAG GAC CAA ATC TTC CCG TAT GCT CAA TCA TCA-3' | |
| Vic11-L194P-R:      | Integrated DNA Technologies | N/A |
| 5'-TGA TGA TTG AGC ATA CGG GAA GAT TTG GTC CTT-3' | |
| Recombinant DNA     |        |            |
| pFUSE-CHIg-hG1      | InvivoGen | Cat#pfuse-hchg1 |
| pFUSE2-CLlg-hK      | InvivoGen | Cat#pfuse2-hclk |
| WSN 8-plasmid reverse genetics | Neumann et al., 1999 | N/A |
| PR8 8-plasmid reverse genetics | Neumann et al., 1999 | N/A |
| pHW2000-chimeric Bris07 HA | Wu et al., 2018 | N/A |
| pHW2000-chimeric Vic11 HA | Wu et al., 2018 | N/A |
| pFast-Bris07 (H3 HA) | Ekiert et al., 2012 | N/A |
| pFast-Vic11 (H3 HA) | Ekiert et al., 2012 | N/A |
| pFast-IVR-165 (H3 HA) | This study | N/A |
| Software and Algorithms |        |            |
| R                   | https://www.r-project.org | RRID: SCR_001905 |
| Python              | https://www.python.org | RRID: SCR_008394 |
| MAFFT version 7.157b | Katoh and Standley, 2013 | RRID: SCR_011811 |
| HKL2000             | Otwinowski and Minor, 1997 | RRID: SCR_015547 |
| Phaser              | McCoy et al., 2007 | RRID: SCR_014219 |

(Continued on next page)
CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ian A. Wilson (wilson@scripps.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell Cultures
HEK 293T cells (human embryonic kidney cells, female) were maintained in DMEM medium supplemented with 10% fetal bovine serum (FBS), 1x MEM non-essential amino acids, and 100 U mL\(^{-1}\) of Penicillin-Streptomycin. MDCK-SIAT1 cells (Madin-Darby canine kidney cells with stable expression of human 2,6-sialtransferase, female) were maintained in DMEM medium supplemented with 10% FBS, 1x MEM non-essential amino acids, and 100 U mL\(^{-1}\) of Penicillin-Streptomycin. Sf9 cells (\textit{Spodoptera frugiperda} ovarian cells, female) and High Five cells (\textit{Trichoplusia ni} ovarian cells, female) were maintained in HyClone insect cell culture medium. ExpiCHO cells (Chinese hamster ovary cells, female) were maintained according to the manufacturer’s instructions (Thermo Fisher Scientific). HEK 293S GnTI\(^{-/-}\) cells (human embryonic kidney cells, female) were maintained in DMEM/F12 medium supplemented with 10% FBS, and 100 U mL\(^{-1}\) of Penicillin-Streptomycin.

Influenza Virus
Recombinant influenza virus was generated based on the A/WSN/33 eight-plasmid reverse genetic system (Neumann et al., 1999). In this study, chimeric 6:2 reassortants were employed with the hemagglutinin (HA) and neuraminidase (NA) ectodomains being replaced by those from H3N2 viruses (Wu et al., 2017a). The HA protein sequence of A/Brisbane/10/2007 (Bris07) wild type (WT) was identical to GenBank: ABW23422.1, which did not contain any egg-adaptive mutations. The HA protein sequence of IVR-165 was identical to GISAID: EPI551807. Transfection was performed in HEK 293T/MDCK-SIAT1 cells (Sigma-Aldrich, catalog number: 05071502-1VL) co-culture (ratio of 6:1) at 60% confluence using lipofectamine 2000 (Life Technologies) according to the manufacturer’s instructions. At 24 hours post-transfection, cells were washed twice with phosphate-buffered saline (PBS) and cell culture medium was replaced with OPTI-MEM medium supplemented with 0.8 m\(\text{g}\) L\(^{-1}\) TPCK-trypsin. Virus was harvested at 72 h post-transfection. For measuring virus titer by the TCID\(_{50}\) (median tissue culture infectious dose) assay, MDCK-SIAT1 cells were washed twice with PBS prior to the addition of virus, and OPTI-MEM medium was supplemented with 0.8 m\(\text{g}\) mL\(^{-1}\) TPCK-trypsin. The virus used for immunization and egg passaging was generated in the same manner, except that the A/PR/8/34 (PR8) eight-plasmid reverse genetic system was used instead to generate the 6:2 reassortant (Neumann et al., 1999).

METHOD DETAILS

Sequence Analysis
A total of 45,218 full-length human H3N2 HA protein sequences were downloaded from the Global Initiative for Sharing Avian Influenza Data (GISAID; http://gisaid.org). Sequences with ambiguous amino acids were removed. Sequence alignment was performed by MAFFT version 7.157b (Katoh and Standley, 2013). Passing history was determined by parsing regular expression in FASTA headers as described (McWhite et al., 2016). Egg-adaptive mutations for a given position were defined as amino-acid variants that were observed only in egg-passaged isolates but not in isolates without any passage in a given year. Those egg-adaptive mutations that were observed in 5 out of 16 years (from 2003 to 2018) were classified as major egg-adaptive mutations.

Construction of Individual Mutants
Individual mutants for validation experiments were constructed using the QuikChange XL Mutagenesis kit (Stratagene) according to the manufacturer’s instructions.

Serial Passages of the Influenza Viruses in Eggs
For each passaging experiment, three nine- to eleven-day embryonated chicken eggs (specific pathogen free) were inoculated with 0.2 ml of 10\(^5\) plaque-forming unit (PFU) ml\(^{-1}\) PR8-A/Brisbane/10/2007 (6:2 reassortant) HA mutant virus at 37°C for 48 hours. The
allantoic fluid from each egg was collected and pooled. Five serial passages were performed for each passaging experiment. The viral RNA was extracted from the allantoic fluid using QIAamp Viral RNA Mini Kit (Qiagen Sciences). The extracted RNA was then reverse transcribed to cDNA using Superscript III reverse transcriptase (Life Technologies). The nucleotide region corresponding to the HA receptor-binding domain was amplified by polymerase chain reaction (PCR) using KOD DNA polymerase (EMD Millipore) according to the manufacturer’s instructions, with primers: 5’-CAC TCT TTC CCT ACA CGA CGC TCT TCC GAT CTX XYG TGC ACT AGT TGC TTC ATC CGS-3’ and 5’-GAC TGG AGT TCA GAC GTG TGC TCC GAT CTG GTG CAT CTG ATC TCA TTA TTG-3’. The sequence XXX represents the barcode sequence for distinguishing samples from different passages. A second PCR was performed to add the rest of the adapter sequence and index to the amplicon using primers: 5’-AAT GAT ACG GCG ACC ACC GAG ATC TAC GCT GAC GAA GAC GGC ATA CGA GAT XXX XXX GTG ACT GGA GTT CAG ACG TGT GCT-3’. Positions annotated by an “X” represented the index sequence for distinguishing different passaging experiments. The final PCR products were submitted for next-generation sequencing using Illumina MiSeq PE300.

Expression, Crystallization and Structural Determination

Briefly, the HA ectodomain, which corresponds to 11–329 (HA1) and 1–176 (HA2) based on H3 numbering, was fused with an N-terminal gp67 signal peptide and a C-terminal BirA biotinylation site, thrombin cleavage site, trimerization domain, and a His6 tag, and then cloned into a customized baculovirus transfer vector (Ekiert et al., 2011). The HA protein sequence of A/Brisbane/10/2007 (Bris07) wild type (WT) was identical to GenBank: ABW23422.1, which did not contain any egg-adaptive mutations. The HA protein sequence of IVR-165 was identical to GISAD: EPI551807. Bris07 mutants were derived from Bris07 WT using QuikChange XL Mutagenesis kit (Stratagene, see above). Recombinant bacmid DNA was generated using the Bac-to-Bac system (Life Technologies). Baculovirus was generated by transfecting purified bacmid DNA into Sf9 cells using FuGene HD (Promega) (Southampton, UK). HA was expressed by infecting suspension cultures of High Five cells (Life Technologies) with baculovirus at an MOI of 5 to 10 and incubating at 28°C with shaking at 110 rpm for 72 hours. The supernatant was concentrated. HA0 was purified using Ni-NTA and buffer exchanged into 20 mM Tris-HCl pH 8.0 and 150 mM NaCl. For crystallization, HA0 was treated with trypsin (New England Biolabs) to remove the C-terminal tag (BirA biotinylation site, thrombin cleavage site, trimerization domain, and the His6 tag) and to produce the cleaved mature HA (HA1/HA2). The trypsin-digested HA was then purified by size exclusion chromatography on a Hiload 16/90 Superdex 200 column (GE Healthcare) in 10 mM Tris pH 8.0, 50 mM NaCl, and 0.02% NaN3. HA crystal screening was carried out using our high-throughput, robotic CrystalMation system (Rigaku) using the sitting drop vapor diffusion method at 4°C and 20°C with each drop consisting of 100 nL protein + 100 nL precipitant. Diffraction-quality crystals for IVR-165 (10 mg/mL) were obtained using 44% 2-methyl-2,4-pentanediol, 0.1 M HEPES pH 7.0 as precipitant at 4°C. Diffraction-quality crystals for Bris07 G186V/L194P (10 mg/mL) were obtained from 0.1 M CAPS pH 10.5 and 29% PEG 400 at 20°C. To generate HA-receptor complexes, crystals were soaked in reservoir solution supplemented with 20 mM of receptor analogs for 2 hours. The resulting crystals were flash cooled, and stored in liquid nitrogen until data collection. Diffraction data were collected at the APS GM/CA-CAT 23ID-B and at the ALS 5.0.3, and then indexed, integrated and scaled using HKL2000 (HKL Research, Charlottesville, VA) (Otwinowski and Minor, 1997). The structure was solved by molecular replacement using Phaser (McCoy et al., 2007) with PDB 4OSN (Lee et al., 2014) or PDB 6AQQ (Wu et al., 2017b) as the molecular replacement model, modeled using Coot (Emsley et al., 2010), and refined using Refmac5 (Murshudov et al., 2011). Ramachandran statistics were calculated using MolProbity (Chen et al., 2010a).

Glycan Array Analysis

Recombinant trimeric HA0 was expressed in HEK 293S GnTI-/- cells, purified and analyzed on a glycan array as previously described (Peng et al., 2017). Briefly, soluble trimeric HA (50 μg mL⁻¹) was pre-complexed with the anti-HIS mouse antibody (Thermo Fisher Scientific) and the Alexa647-linked anti-mouse IgG (Thermo Fisher Scientific) at 4:2:1 molar ratio for 15 minutes on ice in 50 μL PBST. This complex was incubated on the array surface in a humidified chamber for 60 minutes before washing and analysis using an Innoscan 1100AL microarray scanner (Innopsys, Chicago, IL). Fluorescent signal intensity was measured using Mapix (Innopsys) and mean intensity minus mean background of 4 replicate spots was calculated. A complete list of the glycans on the array is presented in Data S1.

Immunization of the Influenza Virus in Mice

Group of six 8-10 weeks old BALB/c mice were inoculated with 1,000 PFU of PR8-Bris07 (6:2 reassortant) wild type virus intranasally. At 16 days post-infection, the mice were further boosted by intraperitoneal injection of 1,000 PFU of same virus mixed with equal volume Addavax (InvivoGen, MF59-like Squalene Adjuvant). The sera of the immunized mice were collected at 24 days post-infection. The serum samples were kept in -20°C for further assay. All animal procedures were carried out under institutionally approved protocols (Approval number: 4884-18) at The University of Hong Kong.

Antigen Binding Assay

A 96-well enzyme-linked immunosorbent assay (ELISA) plate (Nunc MaxiSorp) was first coated overnight with 100 ng per well of purified recombinant Bris07 HA protein in PBS buffer. The plates were then blocked with PBS containing 0.1% Tween 20 and 5% non-fat milk powder at room temperature for 2 hours. Each mouse serum sample was 2-fold serial diluted in PBS buffer and then added into the ELISA plates for 2-hour incubation at 37°C. After extensive washing with PBS containing 0.1% Tween 20, each well in the plate was further incubated with the HRP-sheep anti-mouse second antibody (1:5000, GE Healthcare) for 1 hour at 37°C. Followed by
another extensive washing step, 100 μl mixture of solution A and B (R&D Systems) was added into each well. After 15 minutes incubation, the reaction was stopped by adding 50 μl of 2 M H₂SO₄ solution and analyzed by the Sunrise (Tecan, Grödig, Austria) absorbance microplate reader measured at 450 nm wavelength.

**IgG Expression and Purification**

The C05 (Ekiert et al., 2012) and CR9114 (Dreyfus et al., 2012) heavy chains and light chains were cloned into pFUSE-CHlg-hG1 and pFUSE2-CLlg-hK respectively. The plasmids were co-transfected into ExpiCHO cells (Thermo Fisher Scientific) at 2:1 ratio (light to heavy) using the Max titer protocol as described by the manufacturer’s instructions for the ExpiCHO Expression System (Thermo Fisher Scientific). Full-length IgG proteins were purified from the supernatant using protein G column on AKTAexpress (GE Healthcare).

**Biolayer Interferometry Binding Assay**

An Octet Red instrument (ForteBio) was employed for the biolayer interferometry binding assay. C05 IgG or CR9114 IgG at a concentration of 50 μg mL⁻¹ was loaded onto the anti-human IgG Fc Capture (AHC) Biosensors. Binding kinetics were measured against the indicated HA at 250 nM, 500 nM, 1,000 nM, and 2,000 nM. The data were fit with a 1:1 binding model to estimate the K_d.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

The p-value reported in Figure 5A was computed by the paired Student’s t-test using the R software package.

**DATA AND SOFTWARE AVAILABILITY**

Raw sequencing data have been submitted to the NIH Short Read Archive under accession number: BioProject PRJNA532726. The X-ray coordinates and structure factors have been deposited in the RCSB Protein Data Bank under accession codes 6NS9, 6NSA, 6NSB, 6NSC, 6NSF, 6NSG. Custom python scripts for analyzing the co-occurrence frequencies of egg-adaptive mutations and the next-generation sequencing data have been deposited to https://github.com/wchnicholas/incompatible_egg_muts.